ARED with placebo. Prices decreased libido and impotence were different Elvitegravir EVG than in RST fi. There was no difference in rates of serious adverse events. W During seven years of therapy with finasteride compared with placebo at 882 M Nnern at the age of 18 in the PCPT Similar rates of registered tolerance was not observed. In the placebo group, 28.9% of the men sometimes temporarily treat w Canceled during the 7-year study, compared to 36.8% in the fi nasteride. Reduced volume of ejaculate, erectile dysfunction, loss of libido, gyn Komastie and were h More often in the fi nasteride but the overall risk of these adverse events was low compared to placebo. There was one case of breast cancer in each pass the arm. The mortality tsrate Did not differ from his Signifi cantly between the two groups.
Despite the blockade and subsequent isotype twice 5AR Decline in the serum and prostate DHT, reps Possibility of dutasteride is Similar to the fi nasteride. A 2-year study of dutasteride in the treatment of BPH are shown the rates of impotence, decreased libido, changes Ejakulationsst And Gyn Komastie Similar nasteride fi. Side effects associated with drug were transient with no statistically significant difference was found 2 years. 5AR inhibitors are effective in Rztlichen management of BPH and its effects on the endocrine physiology of the prostate with a relatively low toxicity of t is to study on their use for the prevention and treatment of prostate adenocarcinoma-out. Despite the fact that fi nasteride the only drug effective in the Press Prevention of prostate cancer in a randomized clinical trial, it is not prevention widespread acceptance of its use for the Krebspr.
Recent analyzes of the performance of PSA for detecting prostate cancer with nasteride fi and k-tracking analysis can To L Solution to the issue of tumor grade with finasteride increased Ht. The r Of dutasteride in the Press Be proven prevention of prostate cancer yet. Closing Lich, although vorl INDICATIVE data show an r The m matched 5AR inhibitors in various forms of Multimodalit t therapy for prostate cancer, there were no studies that show cognitive defi improve the survival period with its use in n “each Di T. R 5AR inhibitors in the treatment of prostate cancer is unknown. opportunities for research into the molecular action of androgens appeared in the 1960s, were suitable as radioactive compounds introduced for first experiments.
Wilson1 1968 and Bruchovsky, 2, and Anderson and Liao3 reported that the active form of dihydrotestosterone . Ren intracellular testosterone, dihydrotestosterone receptors and have demonstrated for the first time, two isoforms of the enzyme have been identified: type 1, which is in the skin, the epithelium of the prostate and to a lesser ma e in the stroma and type 2, in which tissue the stroma predominates prostate. A normal growth and function of the prostate, the reduction of testosterone to dihydrotestosterone subject of 5-alpha reductase. over flow of DHT in the pathogenesis of benign prostatic hyperplasia and prostate cancer put together. prevent DHT synthesis by inhibiting the 5 AR has been shown that a remarkable effect on benign prostate disease, low toxicity.4 Well, it’s much st integrated amplifier